Journal List > World J Mens Health > v.31(3) > 1088709

Yang, Ko, Lee, Park, Lee, Moon, Kim, Kim, Cho, Moon, Min, Yang, Son, and Park: Urologist's Practice Patterns Including Surgical Treatment in the Management of Premature Ejaculation: A Korean Nationwide Survey

Abstract

Purpose

According to previous studies, the prevalence of premature ejaculation (PE) in Korea ranges from 11.3% to 33%. However, the actual practice patterns in managing patients with PE is not well known. In this study, we have endeavored to determine how contemporary urologists in Korea manage patients with PE.

Materials and Methods

The e-mailing list was obtained from the Korean Urological Association Registry of Physicians. A specifically designed questionnaire was e-mailed to the 2,421 urologists in Korea from May 2012 to August 2012.

Results

Urologists in Korea diagnosed PE using various criteria: the definition of the International Society for Sexual Medicine (63.4%), Diagnostic and Statistical Manual of Mental Disorders (43.8%), International Statistical Classification of Disease, 10th edition (61.7%), or perceptional self-diagnosis by the patient himself (23.5%). A brief self-administered questionnaire, the Premature Ejaculation Diagnostic Tool, was used by only 42.5% of the urologists. Selective-serotonin reuptake inhibitor (SSRI) therapy was the main treatment modality (91.5%) for PE patients. 40.2% of the urologists used phosphodiesterase type 5 inhibitors, 47.6% behavior therapy, and 53.7% local anesthetics. Further, 286 (54.3%) urologists managed PE patients with a surgical modality such as selective dorsal neurotomy (SDN).

Conclusions

A majority of Korean urologists diagnose PE by a multidimensional approach using various diagnostic tools. Most urologists believe that medical treatment with an SSRI is effective in the management of PE. At the same time, surgical treatment such as SDN also investigated as one of major treatment modality despite the lack of scientific evidence.

INTRODUCTION

Premature ejaculation (PE) is one of the most common sexual dysfunctions in male patients. Previous studies have reported that approximately 30% of adult men suffer from PE [1-3]. In spite of the increasing interest in PE in the field of sexual medicine, our knowledge about the prevalence, etiology, diagnosis, and treatment of PE is scarce. Thus far, multiple factors such as neurobiological cascades related to the metabolism of neurotransmitters, hyperthyroidism, psychological problems, critical life experiences, and penile hypersensitivity are commonly accepted as the etiology of PE. Because of these multiple etiologies of PE, a unified definition of PE has not been established. Currently, the major components of the diagnosis of PE are short intravaginal ejaculatory latency time (IELT), inability to delay ejaculation, and personal distress [4,5].
There are many treatment options for patients with PE, such as psychological education, selective-serotonin reuptake inhibitors (SSRIs), phosphodiesterase type 5 (PDE5) inhibitors, topical anesthetics, selective dorsal neurotomy (SDN), and hyaluronic acid gel glans penis augmentation [6-8]. The preferred management of PE is an on-demand SSRI or daily SSRI. Shindel et al [9] reported that 71% of the urologists in the United States prescribed an SSRI as the initial management of PE. However, many urologists used other treatment options in 35% of the initial treatment cases and 50% of the second-line treatment cases.
Previous studies showed that the prevalence of PE in Korea is between 11.3% and 33% [3,10,11]. However, the daily practice patterns of urologists in the management of patients with PE have not been studied. In this study, we conducted an e-mail-based survey to analyze the practice patterns of Korean urologists in their management of patients with PE.

MATERIALS AND METHODS

After the Institutional Review Board approval was obtained from our hospital, the e-mailing list was retrieved from the Korean Urological Association Registry of Physicians. A specifically designed questionnaire was e-mailed to the 2,421 urologists in Korea from May 2012 to August 2012. Second and third e-mails were sent to non-responders at one and two months after the first e-mail. The questionnaire consisted of five questions about responder demographics, eleven questions about the management of PE, and ten questions about SDN. The survey explored practice characteristics and attitudes, as well as diagnosis and treatment patterns, for the management of PE. There was no compensation provided for participation.

RESULTS

Replies were received from 527 (21.8%) practicing urologists. Two hundreds and ninety (55%) were private clinicians. One hundred and fifty-eight (30%) and 79 urologists (15%) worked at teaching hospitals and non-teaching hospitals, respectively. The mean age was 43.2 (interquartile range [IQR]: 37 to 50) years. The mean period after acquiring board certification was 12.3 (IQR: 5 to 12) years (Table 1).
Approximately half of the urologists (232, 44%) had treated less than two PE patients per week for the past three months. One hundred and sixty-five (31.3%) urologists treated three to five PE patients. Seventy-eight (14.8%) treated six to ten PE patients. Fifty (9.5%) treated more than eleven PE patients a week. A multiple-choice question revealed that urologists in Korea based their diagnosis of PE most commonly on the definition by International Society for Sexual Medicine (ISSM, 63.4%), Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR, 43.8%), International Statistical Classification of Disease, 10th edition (ICD-10, 61.7%), and self-diagnosis by the patient alone (23.5%) in descending order. Only 42.5% of the urologists used the Premature Ejaculation Diagnostic Tool, a brief self-administered questionnaire provided to patients. Diagnosis based on IELT was varied, with 157 (29.8%) considering less than 1 minute as the appropriate criteria, while 22.2% believed that less than 2 minutes was appropriate. Furthermore, 20.7% based their diagnosis on subjective symptoms, irrespective of IELT.
Urologists in Korea treated PE patients with multiple modalities (Fig. 1). SSRI was considered the primary treatment of choice. SSRIs were used by 91.5% of the urologists, and dapoxetine was the most frequently prescribed medication (87.3%) followed by the off-label use of sertraline (29.7%), fluoxetine (19.7%), and paroxetine (11.6%) (Fig. 2). PED5 inhibitors were used by 40.2% of the urologists, and behavioral therapy was used by 47.6% for PE patients. The urologists of 53.7% used local anesthetics. Further, some urologists managed PE patients with surgical modalities such as SDN (286, 54.3%) and hyaluronic acid gel glans or autologous fat glans augmentation (89, 16.9%).
Three hundreds and eighty-four (72.9%) urologists in Korea had prior experience of SDN. Almost all private clinicians (272, 93.5%) reported that they were capable of performing SDN. Half of the hospital-based urologists reported a prior experience of performing SDN (112, 47.5%). Two hundreds and twelve (72.9%) private clinicians, 31 (39.7%) non-teaching hospital urologists, and 48 (30.0%) teaching hospital urologists thought that SDN was necessary for the management of PE patients. SDN was performed most commonly when patients themselves demanded surgical management. SDN was suggested to patients who benefitted from local anesthetics or who suffered from penile hypersensitivity, as diagnosed by a penile vibration perception threshold test. The urologists believed that 57% patients were satisfied with SDN, 39.6% patients considered it 'not bad,' and only 3.4% patients were dissatisfied.
The most common complication of SDN was reported to be the recurrence of PE. Pain or paresthesia on the glans, and edema of the operation site followed (Table 2). Other than the abovementioned complications, hematoma, wound dehiscence, scar formation at the operation site, penile curvature, ejaculation dysfunction, erectile dysfunction, and psychotic disorder were noted by experienced urologists. However, the rate of other complications was very low.

DISCUSSION

Selective SSRIs had led the way to a new era of treatment. However, the understanding of PE is not yet complete. In fact, although an on-demand SSRI, a daily SSRI, or local anesthetics have been introduced for the treatment of PE, many patients continue to suffer from PE due to a lack of definite treatment.
There are several proposed etiologies of PE. With regard to etiologies, PE can be classified largely into lifelong PE and acquired PE. Lifelong PE can be explained by either the hypersensitivity of the 5-HT1A receptor or the hyposensitivity of 5-HT2C [12], and is considered to be related to genetic factors [13,14], biologic hypersensitivity, and hyperexcitability of the glans penis [15]. Erectile dysfunction, prostatitis, thyroid dysfunction, and psychological problems were also considered possible explanations of acquired PE [16-18].
The diagnosis of PE consisted of three principles: short IELT, inability to delay ejaculation, and negative personal consequences. In DSM-IV-TR and ICD-10, the authors believed that distress or interpersonal difficulties and inability to control ejaculation were important components of PE diagnosis along with short sexual intercourse time [5,19]. In ISSM 2008, a vaginal penetration time of within 1 minute was proposed for the diagnosis of PE as the most important factor [4]. In this survey, 63.4% Korean urologists thought that ejaculation within 1 minute of vaginal penetration was the most important diagnostic criterion. However, interpersonal difficulties (43.8%) and ejaculation before the patient and partner could enjoy a sexual interaction sufficiently (61.7%) were considered important as well. 23.5% of the urologists diagnosed PE if the patient thought he had PE.
SSRIs are very effective medications. An SSRI can be taken on-demand or daily or in combination with some other medication. Daily medication with an SSRI showed a significantly elongated stopwatch IELT. In prospective studies, a daily dose of paroxetine (20 mg) increased IELT by up to 783%; a daily dose of sertralin (50 mg), by up to 313%; and a daily dose of fluoxetine (20 to 40 mg), by up to 295% [20]. An on-demand SSRI, dapoxetine, increased the stopwatch IELT from 0.9 minutes to approximately 3 minutes [21]. In this survey, dapoxetine was the most frequently prescribed medication. Although SSRIs are effective oral medications, they have a drawback that cannot be ignored. A previous study reported that 12.6% of the patients (6 of 48) dropped out from a 6-week daily SSRI trial because of side effects [22]. The reported side effects were fatigue, drowsiness, nausea and vomiting, dry mouth, decreased libido, and ED [23].
Korean urologists used local anesthetics in 53.7% of their cases for the management of PE, which is higher than the usage rate of urologists in the United States [9]. Lidocaine gel was the most common local anesthetic used (58.8%), followed by the Severance Secret cream (19.4%) and lidocaine-prilocaine cream (12.0%). There was an opinion that PE is related to penile hyposensitivity in ED patients [24]. However, many previous studies have reported that penile sensitivity was related to ejaculatory latency [25] and that penile hypersensitivity was related to PE [15]. Therefore, a blockage of the relationship between penile hypersensitivity and PE may improve the IELT time. Previous data showed that local anesthetics increased the stopwatch IELT by 5.6 to 7.8 times [26,27]. Local anesthetics did not have general side effects. However, local irritation, loss of penile sensation, and erectile dysfunction were reported. Moreover, a local anesthetic was inconvenient and messy to use and could interfere with arousal and spontaneity. Although it occurred in only a small number of cases, the loss of vaginal sensation with a female partner was reported.
According to the European Urology Guideline Form 2010, the effectiveness of PDE5 inhibitors in the treatment of PE is associated with a 2B level of evidence and a grade C level of recommendation, which reflects that the use of these compounds in patients with PE and without ED is not yet fully established [23]. However, some of the recent data support the favorable effects of PDE5 inhibitors with respect to the treatment of PE. According to the result of the first meta-analysis, the PDE5 inhibitor has an overall positive effect on the treatment of PE as monotherapy or as a component of a combination regimen when compared with SSRI monotherapy [28]. In this study, many of the participating Korean urologists (40.2%) prescribed PDE5 inhibitors for the treatment of PE.
Thus far, across the world, surgical management of PE such as SDN has not been recommended for the treatment of PE because surgical management may induce permanent loss of sexual function, and reliable data on SDN are insufficient [29]. However, SDN increased IELT from 1.1 minutes to 3.8 minutes and improved ejaculation control [8]. Except post-operative wound pain, no other complication was noted. In PE patients who were treated by using computed tomography (CT)-guided cryoablation of the dorsal penile nerve, IELT increased from 54.7 seconds to 182.5 seconds [30]. Four of the 24 patients developed increased flaccidity and improved in time. Further, the glans gel injection was effective for PE patients with glans penis hypersensitivity [7]. In this survey, SDN was one of popular surgical procedures for private clinic urologists in Korea to selected patients who had an effect for local anesthetics or who had a penile hypersensitivity. Urologist answered that 56% of PE patients were satisfied after SDN. Only 3.4% of the PE patients were dissatisfied with it. Although recurrence was observed in 10% of the patients, other complications were very rare.
However, unfortunately, a standard procedure for SDN does not exist. The location of resection and the number of resected dorsal nerves varied among individual urologists. The cost of the procedure varied as well. SDN was more common in private clinics than in hospitals. Hospital urologists, particularly in teaching hospitals, had less interest in SDN. Therefore, a well-designed study should be conducted considering both private and hospital urologists.
Through this nationwide survey, we understood how contemporary urologists in Korea manage patients with PE. Korean urologists believe that subjective symptoms such as interpersonal difficulties and inability to control ejaculation are important along with definitive IELT for the diagnosis of PE. They have many treatment modalities and commonly perform SDN. However, studies or references in support of SDN are lacking. Further studies are required to establish effective treatment options for PE, including surgical treatment.

CONCLUSIONS

A majority of Korean urologists diagnose PE by a multidimensional approach using various diagnostic tools. Most urologists believe that medical treatment with SSRI is effective in the management of PE. At the same time, surgical treatment such as SDN also investigated as one of major treatment modality despite the lack of scientific evidence.

Figures and Tables

Fig. 1
Korean urologist practice pattern for treatment of premature ejaculation. SSRIs: selective-serotonin reuptake inhibitors, SDN: selective dorsal neurotomy, PDE5i: phosphodiesterase 5 inhibitor, TCA: tricyclic antidepressant, HA: hyaluronic acid.
wjmh-31-226-g001
Fig. 2
Preference of selective-serotonin reuptake inhibitors in Korean urologists.
wjmh-31-226-g002
Table 1
Demographics of the study participants
wjmh-31-226-i001

PE: premature ejaculation.

Table 2
Complications after selective dorsal neurotomy
wjmh-31-226-i002

References

1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999; 281:537–544.
2. Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol. 2007; 51:816–823.
crossref
3. Lee SW, Lee JH, Sung HH, Park HJ, Park JK, Choi SK, et al. The prevalence of premature ejaculation and its clinical characteristics in Korean men according to different definitions. Int J Impot Res. 2013; 25:12–17.
crossref
4. McMahon CG, Althof SE, Waldinger MD, Porst H, Dean J, Sharlip ID, et al. An evidence-based definition of lifelong premature ejaculation: report of the International Society for Sexual Medicine (ISSM) ad hoc committee for the definition of premature ejaculation. J Sex Med. 2008; 5:1590–1606.
crossref
5. Waldinger MD, Schweitzer DH. The use of old and recent DSM definitions of premature ejaculation in observational studies: a contribution to the present debate for a new classification of PE in the DSM-V. J Sex Med. 2008; 5:1079–1087.
crossref
6. McMahon CG, Jannini E, Waldinger M, Rowland D. Standard operating procedures in the disorders of orgasm and ejaculation. J Sex Med. 2013; 10:204–229.
crossref
7. Kwak TI, Jin MH, Kim JJ, Moon DG. Long-term effects of glans penis augmentation using injectable hyaluronic acid gel for premature ejaculation. Int J Impot Res. 2008; 20:425–428.
crossref
8. Zhang GX, Yu LP, Bai WJ, Wang XF. Selective resection of dorsal nerves of penis for premature ejaculation. Int J Androl. 2012; 35:873–879.
crossref
9. Shindel A, Nelson C, Brandes S. Urologist practice patterns in the management of premature ejaculation: a nationwide survey. J Sex Med. 2008; 5:199–205.
crossref
10. McMahon CG, Lee G, Park JK, Adaikan PG. Premature ejaculation and erectile dysfunction prevalence and attitudes in the Asia-Pacific region. J Sex Med. 2012; 9:454–465.
crossref
11. Hwang I, Yang DO, Park K. Self-reported prevalence of and attitudes toward premature ejaculation in a community-based study of married couples. World J Mens Health. 2013; 31:70–75.
crossref
12. Waldinger MD. The neurobiological approach to premature ejaculation. J Urol. 2002; 168:2359–2367.
crossref
13. Jern P, Santtila P, Witting K, Alanko K, Harlaar N, Johansson A, et al. Premature and delayed ejaculation: genetic and environmental effects in a population-based sample of Finnish twins. J Sex Med. 2007; 4:1739–1749.
crossref
14. Waldinger MD. Toward evidence-based genetic research on lifelong premature ejaculation: a critical evaluation of methodology. Korean J Urol. 2011; 52:1–8.
crossref
15. Xin ZC, Choi YD, Rha KH, Choi HK. Somatosensory evoked potentials in patients with primary premature ejaculation. J Urol. 1997; 158:451–455.
crossref
16. Screponi E, Carosa E, Di Stasi SM, Pepe M, Carruba G, Jannini EA. Prevalence of chronic prostatitis in men with premature ejaculation. Urology. 2001; 58:198–202.
crossref
17. Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab. 2005; 90:6472–6479.
crossref
18. Althof SE. Psychological treatment strategies for rapid ejaculation: rationale, practical aspects, and outcome. World J Urol. 2005; 23:89–92.
crossref
19. Smolík P. The new international psychiatric classification ICD-10. I. General principles and historical development. Cas Lek Cesk. 1994; 133:298–302.
20. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res. 2004; 16:369–381.
crossref
21. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. Dapoxetine Study Group. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006; 368:929–937.
crossref
22. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998; 18:274–281.
23. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010; 57:804–814.
crossref
24. Rowland DL, Cooper SE, Slob AK. Re: Penile sensitivity in patients with primary premature ejaculation. J Urol. 1997; 158:187–188.
crossref
25. Rowland DL, Haensel SM, Blom JH, Slob AK. Penile sensitivity in men with premature ejaculation and erectile dysfunction. J Sex Marital Ther. 1993; 19:189–197.
crossref
26. Choi HK, Jung GW, Moon KH, Xin ZC, Choi YD, Lee WH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology. 2000; 55:257–261.
crossref
27. Berkovitch M, Keresteci AG, Koren G. Efficacy of prilocaine-lidocaine cream in the treatment of premature ejaculation. J Urol. 1995; 154:1360–1361.
28. Asimakopoulos AD, Miano R, Finazzi Agrò E, Vespasiani G, Spera E. Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? A systematic review and meta-analysis. J Sex Med. 2012; 9:2404–2416.
crossref
29. Althof SE, Abdo CH, Dean J, Hackett G, McCabe M, McMahon CG, et al. International Society for Sexual Medicine. International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med. 2010; 7:2947–2969.
crossref
30. David Prologo J, Snyder LL, Cherullo E, Passalacqua M, Pirasteh A, Corn D. Percutaneous CT-guided cryoablation of the dorsal penile nerve for treatment of symptomatic premature ejaculation. J Vasc Interv Radiol. 2013; 24:214–219.
crossref

Supplementary Material

Supplementary Material

TOOLS
ORCID iDs

Kwangsung Park
https://orcid.org/http://orcid.org/0000-0001-8827-162X

Similar articles